Prostate Cancer - Results from #24520

Editor's Commentary - A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range July 19, 2011

Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction - Abstract July 18, 2011

Effect on sexual function of a vacuum erection device post-prostatectomy - Abstract July 18, 2011

Saturation biopsies for prostate cancer detection: Effectiveness, safety and predictive factors - Abstract July 18, 2011

Expression of hedgehog pathway components in prostate carcinoma microenvironment: Shifting the balance towards autocrine signalling - Abstract July 18, 2011

The impact of PSA testing frequency on prostate cancer incidence and treatment in older men - Abstract July 18, 2011

Assessing response in bone metastases in prostate cancer with diffusion weighted MRI - Abstract July 18, 2011

Prostate-specific antigen 1.5-4.0 ng/mL: A diagnostic challenge and danger zone - Abstract July 18, 2011

Location of residual cancer after transrectal high-intensity focused ultrasound ablation for clinically localized prostate cancer - Abstract July 18, 2011

Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: Results of the French Genito-Urinary Tumor Group (GETUG) P01 trial July 18, 2011

Editor's Commentary - Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: Results of the French Genito-Urinary Tumor Gr July 18, 2011

Editor's Commentary - The relationship between prostate specific antigen change and biopsy progression in patients with prostate cancer on active surveillance July 18, 2011

Single-arc volumetric-modulated arc therapy can provide dose distributions equivalent to fixed-beam intensity-modulated radiation therapy for prostatic irradiation with seminal vesicle and/or lymph node involvement - Abstract July 17, 2011

The role of vitamin D, estrogen, calcium sensing receptor genotypes and serum calcium in the pathogenesis of prostate cancer - Abstract July 15, 2011

Potential prostate cancer drug target: Bioactivation of androstanediol by conversion to dihydrotestosterone - Abstract July 15, 2011

Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer - Abstract July 15, 2011

Predictive models for worsening prognosis in potential candidates for active surveillance of presumed low-risk prostate cancer - Abstract July 15, 2011

Enhanced antitumor activity of low-dose continuous administration schedules of topotecan in prostate cancer - Abstract July 15, 2011

Diabetes and prostate cancer risk in the REDUCE trial - Abstract July 15, 2011

Lateral spine radiographs before androgen deprivation treatment detect a high incidence of undiagnosed vertebral fragility fractures in men with advanced prostate cancer - Abstract July 14, 2011

Page 1227 of 1288